Yes I wouldn’t be surprised if the pricing was more in the $35k to $45k range.
IMO we have 2 major IP advantages.
1. Our one piece valve (as nature intended it) using our superior Adapt technology with a current 10 years history of little to no calcification.
2. The patent pending IP of our TAVR device supplied in sterile solution cutting out 45 minutes of the operation prep time.
For a substantial deal to be done I would assume an exclusive supply agreement on both would be required.
My expectations are only tempered somewhat considering we have an exclusive supply agreement with 4C medical, which has had no upfront fees payable to date.
I assume this exclusive supply agreement is for the TMVR space.
Who knows, perhaps some fees will kick in if and when they get approval for their device.
TAVR gains interest at JPM, page-34
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |